Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
Vivek Subbiah(Sarah Cannon), Erica Evans(Blueprint Medicines (United States)), Marcia S. Brose(Sidney Kimmel Cancer Center), Michelle Maynard(Blueprint Medicines (United States)), Christoph Lengauer(Blueprint Medicines (United States)), Steven P. Miller(University of Toronto), Lori J. Wirth(Massachusetts General Hospital), Matthew H. Taylor(Providence Portland Medical Center), Paul Fleming(Blueprint Medicines (United States)), Qiongfang Cao(Blueprint Medicines (United States)), Timothy J. Guzi(Casma Therapeutics (United States)), Michael Palmer(Blueprint Medicines (United States)), Elena Garralda(Memorial Sloan Kettering Cancer Center), Rami Rahal(Blueprint Medicines (United States)), Beni B. Wolf(Blueprint Medicines (United States)), Michael P. Sheets(Blueprint Medicines (United States)), Justin F. Gainor(Harvard University), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Wei Hu(Blueprint Medicines (United States)), Douglas Wilson(Blueprint Medicines (United States)), Kevin Wilson(Blueprint Medicines (United States)), Lucian DiPietro(Blueprint Medicines (United States)), Jason D. Brubaker(Blueprint Medicines (United States)), Joseph L. Kim(Blueprint Medicines (United States))
Cited by 392
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Is a p53-Regulated Inhibitor of G2/M Progression
|Molecular Cell|1997|1.2k